Kras mutations and resistance to anti-egfr treatment
OwnerAlberto Bardelli, Federica Di Nicolantonio +2inventors
InventorsAlberto Bardelli, Federica Di Nicolantonio, Salvatore Siena, David B. Solit
Life of this patent
Estimating the term…
Abstract
The disclosure provides compositions and methods for detecting and predicting acquired resistance to anti-EGFR treatment in colorectal cancers. Also provided are compositions and methods of preventing, reversing or delaying the acquired resistance. The present disclosure also provides kits for use in the methods described herein.
Claims18
A method of predicting if a subject being treated for colorectal cancer with anti-EGFR therapy will develop drug resistance, the method comprising,
- obtaining a biological sample from said subject, and assaying said sample for an alteration in KRAS expression,
- wherein if an alteration in KRAS expression is detected, the subject is more likely to develop drug resistance to said anti-EGFR therapy.
A method of preventing, reducing or delaying the onset of drug resistance to anti-EGFR therapy, the method comprising,
- administering, to a subject having an alteration in KRAS expression, a MEK inhibitor in combination with said anti-EGFR therapy.
A method of detecting a KRAS mutation, the method comprising assaying a biological sample from a human subject for a KRAS mutation selected from G13D, G12R, Q61H, and A146T in the human KRAS amino acid sequence of SEQ ID NO:
- 2 or 4.
Dependencies are inferred from the claim text.